We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application (ABBA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00621114
First Posted: February 22, 2008
Last Update Posted: April 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Gambro Dialysatoren GmbH
Information provided by (Responsible Party):
Baxter Healthcare Corporation
  Purpose
The clinical study aims at providing data on antimicrobial efficiency and a supposed additional preventive effect on catheter-related infections of a catheter with antibacterial surface coating in comparison to standard catheters without coating.

Condition Intervention
Hemodialysis Device: GamCath® central venous catheter Device: GamCath Dolphin® Protect central venous catheter

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application

Further study details as provided by Baxter Healthcare Corporation:

Primary Outcome Measures:
  • Bacterial colonisation of the catheter surface [ Time Frame: after explantation ]

Secondary Outcome Measures:
  • venous and arterial pressure [ Time Frame: during dialysis ]
  • catheter dwell time [ Time Frame: at explantation ]
  • exit site appearance [ Time Frame: at routine catheter care ]
  • blood parameters [ Time Frame: during dialysis ]

Enrollment: 69
Study Start Date: August 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
Device: GamCath® central venous catheter
Choice of central venous catheter type
Other Name: GamCath® catheter
Experimental: 2
Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
Device: GamCath Dolphin® Protect central venous catheter
Choice of central venous catheter type
Other Name: GamCath Dolphin® Protect

Detailed Description:

Central venous catheters are increasingly used to provide long-term venous access, e.g. after failure of the primary arteriovenous fistula, and they are the first choice in case of an acute need for extracorporeal therapy. Microbial adhesions and biofilm formation have been implicated in serious infections associated with the use of indwelling catheters.

In view of the necessity to reduce catheter-related bloodstream infections and of the inadequacy of currently available antimicrobially coated devices, a new antimicrobial catheter surface was developed.

The clinical study described below aims at providing further data on antimicrobial efficiency and a supposed additional preventive effect on catheter-related infections.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • central venous catheter placement
  • Need for extracorporeal renal replacement therapy (acute and chronic renal failure)
  • Anticipated duration of dialysis therapy less than or equal to 30 days
  • Age between 18 and 85 years
  • Written informed consent

Exclusion Criteria:

  • Known Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) infection
  • Known pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00621114


Locations
Germany
Universitaetsklinikum Tuebingen
Tuebingen, Germany, 72076
Sponsors and Collaborators
Baxter Healthcare Corporation
Gambro Dialysatoren GmbH
Investigators
Principal Investigator: Teut Risler, Prof. Dr. Universitaetsklinikum Tuebingen
  More Information

Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT00621114     History of Changes
Other Study ID Numbers: Study No 2007_MBR_003
ISRCTN39140035 ( Registry Identifier: ISRCTN )
First Submitted: January 31, 2008
First Posted: February 22, 2008
Last Update Posted: April 20, 2017
Last Verified: January 2010

Keywords provided by Baxter Healthcare Corporation:
Dialysis, Extracorporeal
Dialysis, Renal
Extracorporeal Dialysis
Hemodialysis